S-3

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

Retrieved on: 
Donnerstag, Mai 9, 2024
Investment, Research, Security (finance), Guggenheim Partners, Lung cancer, Carcinoma, Form, Patient, Genelux Corporation, S-3, Clinical trial, G&A, Platinum, Pharmaceutical industry

WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.

Key Points: 
  • WESTLAKE VILLAGE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.
  • In the first quarter of 2024, we filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission.
  • Research and development (R&D) expenses were $4.0 million for the first quarter of 2024, as compared to $2.8 million for the first quarter 2023, respectively.
  • General and administrative (G&A) expenses were $4.1 million in the first quarter of 2024, as compared to $3.8 million for the first quarter of 2023.

Genesis Energy, L.P. Upsizes and Prices Public Offering of Senior Notes

Retrieved on: 
Montag, Mai 6, 2024
Other Energy, Oil, Gas, Energy, Trucking, Chemicals, Plastics, Maritime, Transport, Manufacturing, Sale, RBC Capital Markets, Genesis Energy, Security (finance), Partnership, Gulf of Mexico, Form, BofA Securities, S-3, BNP Paribas, Wells Fargo

Genesis Energy, L.P. (NYSE: GEL) today announced that it has priced a public offering of $700,000,000 in aggregate principal amount of 7.875% senior unsecured notes due 2032 (the “notes”).

Key Points: 
  • Genesis Energy, L.P. (NYSE: GEL) today announced that it has priced a public offering of $700,000,000 in aggregate principal amount of 7.875% senior unsecured notes due 2032 (the “notes”).
  • The offering of the notes was upsized from the previously announced $500,000,000 in aggregate principal amount of the notes.
  • The offering of the notes is expected to settle and close on May 9, 2024, subject to customary closing conditions.
  • This press release does not constitute a notice of redemption under the indenture governing the 6.250% senior unsecured notes due 2026.

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Retrieved on: 
Freitag, Mai 3, 2024
Titan, Sale, Idiopathic pulmonary fibrosis, Prospectus, Aileron, ALRN, Security (finance), Form, Exercise, Patient, Fibrosis, S-3, Therapy

Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68.

Key Points: 
  • Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68.
  • The aggregate gross proceeds of the offering were approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aileron, and excluding any proceeds that may be received from exercise of the warrants.
  • Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.
  • The offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement.

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Freitag, Mai 3, 2024
Janus, Sale, Prospectus, Montgomery Street, Suite, Security (finance), Form, BLA, S-3, Attention, Telephone

The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full.

Key Points: 
  • The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full.
  • The closing of the offering is expected to occur on or about May 7, 2024, subject to the satisfaction of customary closing conditions.
  • The offering included participation from both new and existing investors, including Adage Capital Partners, L.P., Janus Henderson Investors, Nantahala Capital, Suvretta Capital, Vivo Capital, and other healthcare-dedicated investors.
  • The gross proceeds to Abeona from this offering are expected to be approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses.

Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants

Retrieved on: 
Freitag, April 26, 2024
Sale, Prospectus, Security (finance), SVB Securities, Form, PALO, State Street, S-3, Telephone

PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock, and (ii) to certain investors, pre-funded warrants to purchase up to an aggregate of 16,000,000 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 16,000,000 shares of common stock.

Key Points: 
  • PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,000,000 shares of common stock, and (ii) to certain investors, pre-funded warrants to purchase up to an aggregate of 16,000,000 shares of common stock and accompanying common stock warrants to purchase up to an aggregate of 16,000,000 shares of common stock.
  • Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.75, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.7499.
  • All of the shares, pre-funded warrants and common stock warrants in the offering are being sold by Vincerx.
  • The gross proceeds to Vincerx from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $16.5 million.

Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants

Retrieved on: 
Donnerstag, April 25, 2024
Sale, Prospectus, Security (finance), SVB Securities, Form, PALO, State Street, S-3, Telephone

PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock.

Key Points: 
  • PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying common stock warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock and accompanying common stock warrants to purchase shares of its common stock.
  • All of the shares, pre-funded warrants and common stock warrants in the proposed offering will be offered by Vincerx.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement.

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Donnerstag, April 25, 2024
Sale, Prospectus, Acceleration, Form, Exercise, Patient, S-3, Telephone, Security (finance)

The warrants include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzheimer’s Disease program (as further described  below).

Key Points: 
  • The warrants include an acceleration clause upon positive top-line data in the Company’s Phase 2 Alzheimer’s Disease program (as further described  below).
  • The offering was priced at-the-market under Nasdaq rules based on the average of the previous 5-days’ closing prices, or $9.84 per share which includes $0.125 per warrant.
  • The gross proceeds of this offering are approximately $9.7 million before deducting placement agent fees and expenses.
  • The closing of the offering is expected to occur on or about April 29, 2024, subject to the satisfaction of customary closing conditions.

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Retrieved on: 
Mittwoch, April 24, 2024
Sale, Prospectus, Cancer, Morgan Stanley, Vanderbilt Avenue, Security (finance), Form, TD Securities, Varick Street, Patient, 2nd Floor, S-3, TCR, Attention, Therapy, Telephone, Needham & Company

Morgan Stanley and TD Cowen acted as joint book-running managers for the offering.

Key Points: 
  • Morgan Stanley and TD Cowen acted as joint book-running managers for the offering.
  • LifeSci Capital acted as lead manager, and BTIG, H.C. Wainwright & Co. and Needham & Company acted as co-managers for the offering.
  • The offering was made only by means of a preliminary prospectus supplement and accompanying filed with the SEC.
  • A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC.

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

Retrieved on: 
Montag, April 22, 2024
Sale, Prospectus, Acceleration, Suite, Form, Exercise, Patient, S-3, Telephone, Security (finance)

The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering.

Key Points: 
  • The warrants give the investor the right to purchase 571,592 additional shares of its common stock in a registered direct offering.
  • The offering was priced at the market based on the Friday, April 19th Nasdaq consolidated closing bid price of $8.32 per share.
  • The exercise price of the warrants is $9.152, which represents a 10% premium to the price at which the common shares were offered.
  • The gross proceeds of this offering are approximately $4.8 million before deducting placement agent fees and expenses.

Bridger Aerospace Announces Closing of $9.8 Million Registered Direct Offering

Retrieved on: 
Mittwoch, April 17, 2024
Sale, Prospectus, ATTN:, Form, S-3, Telephone

BELGRADE, Mont., April 17, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “the Company”) (NASDAQ: BAER) today announced the closing of a registered direct offering of 2,183,366 shares of common stock, resulting in gross proceeds of approximately $9.8 million, before deducting placement agent commissions and other offering expenses.

Key Points: 
  • BELGRADE, Mont., April 17, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “the Company”) (NASDAQ: BAER) today announced the closing of a registered direct offering of 2,183,366 shares of common stock, resulting in gross proceeds of approximately $9.8 million, before deducting placement agent commissions and other offering expenses.
  • 808,080 of the shares sold in the offering were acquired by certain directors and executive officers of Bridger.
  • Stifel, Nicolaus & Company, Incorporated acted as the exclusive placement agent for the offering.
  • This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No.